Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
Sponsor: Ascletis Pharma (China) Co., Limited
Summary
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.
Official title: A Phase I, Randomized, Double-blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of ASC50 Tablets in Healthy Adult Participants and Adult Participants With Mild to Moderate Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
94
Start Date
2025-06
Completion Date
2026-06
Last Updated
2025-06-17
Healthy Volunteers
Yes
Conditions
Interventions
ASC50 tablets or matching placebo
Drug: ASC50 administered orally Drug: Placebo administered orally
Locations (1)
Ascletis Clinical Site
Miami, Florida, United States